We use cookies on our website, which are text files containing small amounts of information that are downloaded to your computer or mobile device. To find out more about the cookies we use please click here.

Some of these cookies are strictly necessary for operation of this site. Other, non-essential cookies are used for measuring website performance (which is all aggregated and anonymised) and may share this information with Google. To consent to non-essential cookies, click "Accept all non-essential cookies".

Locate Bio is a spinout from the University of Nottingham and is a specialist in regenerative medicine.

Locate Bio (Locate) is a specialist regenerative medicine and medical device company based in Nottingham. As one of the leaders in its field, the Locate team has been working for over a decade on developing a novel drug delivery system (TAOS®) and associated gene editing technologies (IntraStem), with an initial focus on orthopaedic applications.

Its lead product is a treatment for osteomyelitis, for which Locate has partnered with a major European medical device developer. In addition, it is developing a product to precisely control bone growth, a significant clinical problem with a $7.0billion worldwide market. Mercia's investment will be used to further expand Locate's existing product portfolio as well as new product opportunities utilising its IntraStem technology. The global regenerative medicine market is estimated to be worth $20.0billion and is forecast to be growing at a CAGR of 26.0%.

Other portfolio companies

© Mercia Technologies 2018

Terms and conditions Privacy policy

Designed and built by Onespacemedia